Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

OTC Monograph Woes No Surprise To FDA Commissioner Nominee Gottlieb

Executive Summary

Gottlieb was asked only one question about OTC drug regulation during his confirmation hearing before the Senate HELP Committee, but it covered a large part of FDA's current concerns about the OTC market.

Advertisement

Related Content

Gottlieb's Confirmation: He's Willing To Disagree With Trump, Sec. Price
OTC Monograph Reform, User Fee Legislation Coming 'Any Day' – CHPA
'Real Challenge' To Improve OTC Monograph Program Without User Fees – FDA
Behind-The-Counter Guidance Stalled, But Interest Grows To Expand Access
Evolving Switch Scene Could Drive Nonprescription Reimbursement – Gottlieb

Topics

Advertisement
UsernamePublicRestriction

Register

PS120381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel